NYSE:CTLT

Catalent (CTLT) Stock Forecast, Price & News

$45.53

-0.18 (-0.39%)

(As of 09/29/2023 ET)

Compare

Today's Range: $45.30
▼
$46.36
50-Day Range: $44.20
▼
$50.20
52-Week Range: $31.45
▼
$81.72

Volume: 1.98 million shs
Average Volume: 1.75 million shs
Market Capitalization: $8.21 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $53.17

Catalent MarketRank™ Forecast

Analyst Rating: Hold
2.31 Rating Score
Upside/Downside: 16.8% Upside
$53.17 Price Target
Short Interest: Healthy
5.71% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: 0.19
Based on 17 Articles This Week
Insider Trading: Acquiring Shares
$1.11 M Bought Last Quarter
Proj. Earnings Growth: 118.57%
From $0.70 to $1.53 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

173rd out of 972 stocks

Pharmaceutical Preparations Industry

61st out of 455 stocks

3.2

Analyst's Opinion

Consensus Rating
Catalent has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 5 buy ratings, 7 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $53.17, Catalent has a forecasted upside of 16.8% from its current price of $45.53.
Amount of Analyst Coverage
Catalent has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
5.71% of the outstanding shares of Catalent have been sold short.
Short Interest Ratio / Days to Cover
Catalent has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Catalent has recently decreased by 6.28%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Catalent does not currently pay a dividend.
Dividend Growth
Catalent does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Catalent has received a 72.90% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services", "Clinical research services", and "Pharmacovigilance services" products. See details.
Environmental Sustainability
The Environmental Impact score for Catalent is -0.85.

1.8

News and Social Media Coverage

News Sentiment
Catalent has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 17 news articles for Catalent this week, compared to 8 articles on an average week.
Search Interest
Only 8 people have searched for CTLT on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Catalent to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Catalent insiders have bought 346.33% more of their company's stock than they have sold. Specifically, they have bought $1,105,020.00 in company stock and sold $247,577.00 in company stock.
Percentage Held by Insiders
Only 0.58% of the stock of Catalent is held by insiders.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Catalent are expected to grow by 118.57% in the coming year, from $0.70 to $1.53 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Catalent is -35.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Catalent is -35.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
Catalent has a PEG Ratio of 3.59. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Catalent has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Catalent (NYSE:CTLT) Stock

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

CTLT Price History

30 days | 90 days | 365 days | Advanced Chart

CTLT Stock News Headlines

September 20, 2023 | marketbeat.com

Flee to Healthcare Stocks if Recession Rears its Head? (CTLT)

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

October 1, 2023 | americanbankingnews.com

Catalent (NYSE:CTLT) Price Target Cut to $50.00

October 1, 2023 | Behind the Markets (Ad)

[BREAKING] Pentagon to Spend Billions on "Living Missile"

Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!

September 30, 2023 | americanbankingnews.com

Brokers Set Expectations for Catalent, Inc.'s Q2 2024 Earnings (NYSE:CTLT)

September 29, 2023 | americanbankingnews.com

FY2026 EPS Estimates for Catalent, Inc. Cut by Analyst (NYSE:CTLT)

September 28, 2023 | finance.yahoo.com

Catalent (CTLT) Down 6.5% Since Last Earnings Report: Can It Rebound?

September 18, 2023 | finance.yahoo.com

Catalent Appoints David McErlane as Biologics Segment Leader

September 16, 2023 | msn.com

Activist Elliott makes inroads at Catalent to build value. Here’s what could happen next

October 1, 2023 | Behind the Markets (Ad)

[BREAKING] Pentagon to Spend Billions on "Living Missile"

September 15, 2023 | finance.yahoo.com

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

September 11, 2023 | finance.yahoo.com

Is Catalent Inc (CTLT) Set to Underperform? Analyzing the Factors Limiting Growth

September 5, 2023 | msn.com

Catalent shares rise after Argus upgrades rating on post-COVID strategy

September 5, 2023 | msn.com

Argus upgrades Catalent to buy, cites transition to biologics production

September 4, 2023 | finance.yahoo.com

Unraveling the Future of Catalent Inc (CTLT): A Deep Dive into Key Metrics

September 1, 2023 | finance.yahoo.com

Why Catalent Stock Zoomed 12% Higher This Week

September 1, 2023 | msn.com

B of A Securities Maintains Catalent (CTLT) Underperform Recommendation

August 31, 2023 | markets.businessinsider.com

15 Analysts Have This to Say About Catalent

August 31, 2023 | finance.yahoo.com

Compared to Estimates, Catalent (CTLT) Q4 Earnings: A Look at Key Metrics

August 30, 2023 | markets.businessinsider.com

Catalent's Activist Board Presence To Boost Operational Recovery, Analyst Says

August 30, 2023 | markets.businessinsider.com

RBC Capital Maintains Outperform Rating for Catalent: Here's What You Need To Know

August 30, 2023 | msn.com

Catalent Announces Cooperation Agreement With Elliot Investment: Analysts’ Price Recommendations

August 30, 2023 | insidermonkey.com

Catalent, Inc. (NYSE:CTLT) Q4 2023 Earnings Call Transcript

August 30, 2023 | msn.com

Catalent reaches settlement with Elliott to explore strategic review

August 30, 2023 | markets.businessinsider.com

Catalent (CTLT) Gets a Buy from RBC Capital

August 29, 2023 | msn.com

Shares of Wegovy Partner Catalent Jump After Striking Deal With Activist Investor Elliott

August 29, 2023 | finance.yahoo.com

Catalent (CTLT) Q4 Earnings Miss Estimates

August 29, 2023 | uk.finance.yahoo.com

Is Catalent (CTLT) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap

See More Headlines

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings: 8/29/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:CTLT
CUSIP: N/A
CIK: 1596783
Web: www.catalent.com
Phone: (732) 537-6200
Fax: 732-537-6480
Employees: 19,000
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $53.17
High Stock Price Forecast: $85.00
Low Stock Price Forecast: $43.00
Forecasted Upside/Downside: +16.8%
Consensus Rating: Hold
Rating Score (0-4): 2.31
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.30)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 65.04
P/E Growth: 3.61
Net Income: $-232,000,000.00
Net Margins: -5.43%
Pretax Margin: -7.37%
Return on Equity: 3.24%
Return on Assets: 1.43%

Debt

Debt-to-Equity Ratio: 0.93
Current Ratio: 1.78
Quick Ratio: 1.27

Sales & Book Value

Annual Sales: $4.28 billion
Price / Sales: 1.92
Cash Flow: $1.44 per share
Price / Cash Flow: 31.57
Book Value: $25.71 per share
Price / Book: 1.77

Miscellaneous

Outstanding Shares: 180,270,000
Free Float: 179,226,000
Market Cap: $8.21 billion
Optionable: Optionable
Beta: 1.23

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. John J. Greisch M.B.A. (Age 68)
Exec. Chairman
Comp: $125k

Mr. Alessandro Maselli (Age 51)
Pres, CEO & Director
Comp: $1.53M

Dr. Aristippos Gennadios Ph.D. (Age 57)
Group Pres of Pharma & Consumer Health Segment
Comp: $1.13M

Mr. Matti M. Masanovich (Age 51)
Sr. VP & CFO

Ms. Karen Murphy Santiago (Age 52)
VP & Chief Accounting Office

Mr. Charles Lickfold (Age 49)
Sr. VP & Chief Information Officer

Mr. Paul Surdez
VP of Investor Relations

Mr. Joseph A. Ferraro J.D. (Age 44)
Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec.

Mr. Michael J. Grippo (Age 54)
Sr. VP of Strategy & Corp. Devel.

Ms. Lisa Evoli (Age 53)
Sr. VP & Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CTLT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CTLT, but not buy additional shares or sell existing shares.
View CTLT analyst ratings or view top-rated stocks.
What is Catalent's stock price forecast for 2023?: 13 Wall Street analysts have issued 1 year price targets for Catalent's stock. Their CTLT share price forecasts range from $43.00 to $85.00. On average, they predict the company's stock price to reach $53.17 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price.
View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts.
How have CTLT shares performed in 2023?: Catalent's stock was trading at $45.01 at the beginning of 2023. Since then, CTLT stock has increased by 1.2% and is now trading at $45.53.
View the best growth stocks for 2023 here.
Are investors shorting Catalent?: Catalent saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 10,300,000 shares, a decline of 6.3% from the August 31st total of 10,990,000 shares. Based on an average daily volume of 2,440,000 shares, the days-to-cover ratio is currently 4.2 days.
View Catalent's Short Interest.
When is Catalent's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our CTLT earnings forecast.
How were Catalent's earnings last quarter?: Catalent, Inc. (NYSE:CTLT) released its earnings results on Tuesday, August, 29th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by $0.02. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.05 billion. Catalent had a positive trailing twelve-month return on equity of 3.24% and a negative net margin of 5.43%. Catalent's quarterly revenue was down 15.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.12 earnings per share.
Read the conference call transcript.
What ETFs hold Catalent's stock?: ETFs with the largest weight of Catalent (NYSE:CTLT) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Invesco Biotechnology & Genome ETF (PBE), iShares U.S. Pharmaceuticals ETF (IHE), VanEck Pharmaceutical ETF (PPH), Invesco S&P 500 Equal Weight Health Care ETF (RYH), Invesco S&P 500 Equal Weight Health Care ETF (RSPH) and WisdomTree BioRevolution Fund (WDNA).
What guidance has Catalent issued on next quarter's earnings?: Catalent issued an update on its FY 2024 earnings guidance on Tuesday, August, 29th. The company provided earnings per share guidance of $0.62-$0.96 for the period, compared to the consensus earnings per share estimate of $1.14. The company issued revenue guidance of $4.30 billion-$4.50 billion, compared to the consensus revenue estimate of $4.19 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?: 391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.
What other stocks do shareholders of Catalent own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).
What is Catalent's stock symbol?: Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."
How do I buy shares of Catalent?: Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Catalent's stock price today?: One share of CTLT stock can currently be purchased for approximately $45.53.
How much money does Catalent make?: Catalent (NYSE:CTLT) has a market capitalization of $8.21 billion and generates $4.28 billion in revenue each year. The company earns $-232,000,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.
How many employees does Catalent have?: The company employs 19,000 workers across the globe.
How can I contact Catalent?: Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Catalent (CTLT) Stock Forecast, Price & News

Catalent MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Catalent (NYSE:CTLT) Stock

CTLT Price History

CTLT Stock News Headlines

CTLT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

CTLT Stock - Frequently Asked Questions

Overall MarketRank^™